Publicaciones en las que colabora con Laura Torella (6)

2024

  1. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1

    EMBO molecular medicine, Vol. 16, Núm. 1, pp. 112-131

  2. Gene editing in liver diseases

    FEBS Letters

  3. Protective role of RIPK1 scaffolding against HDV-induced hepatocyte cell death and the significance of cytokines in mice

    PLoS Pathogens, Vol. 20, Núm. 5

2022

  1. mRNA and gene editing: Late breaking therapies in liver diseases

    Hepatology, Vol. 76, Núm. 3, pp. 869-887

2020

  1. In Vitro and In Vivo Genetic Disease Modeling via NHEJ-Precise Deletions Using CRISPR-Cas9

    Molecular Therapy - Methods and Clinical Development, Vol. 19, pp. 426-437

2018

  1. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

    Nature Communications, Vol. 9, Núm. 1